Stelara preferable agent for the treatment of elderly patients with psoriasis.

[Caroline]

This study looked at the efficacy and safety of Stelara (ustekinumab) (UST) treatment in elderly patients with psoriasis, and suggests it is the preferable agent for the elderly.

Quote:

---

The ratio of the elderly among psoriasis patients has been increasing. However, satisfactory long-term management of psoriasis for the elderly is challenging because of the more frequent presence of comorbidities, and the higher risk of adverse events from systemic therapeutic agents than younger patients.

The use otf ustekinumab (UST) appears to be an appropriate systemic treatment because it is considered less likely to cause adverse events than other systemic treatments, as well as necessitating fewer hospital visits.

Our retrospective study aimed to evaluate the efficacy and safety profile of UST in elderly patients with psoriasis. The study included 24 patients aged over 65 years (range, 65–88 years; mean, 73.1 years) with moderate to severe plaque psoriasis with impaired quality of life.

Efficacy and safety were assessed over a 1-year period using the Psoriasis Area and Severity Index (PASI) and the Dermatology Live Quality Index (DLQI).

The efficacy was evaluated by the proportion of subjects who achieved ≥75% reduction in PASI score (PASI 75). PASI 75 responses were 56.5% at week 16, 59.1% at week 28, and 60.0% at week 52.

None of the patients developed any serious infection during the 1-year treatment. The mean DLQI score at weeks 0, 16, 28, and 52 was 7.8 ± 6.0, 2.5 ± 3.4, 1.4 ± 1.7, and 1.2 ± 1.7, respectively.

UST showed sufficient efficacy for elderly patients with psoriasis without any serious infection over the 1-year treatment. Our results suggest that UST is the preferable agent for the treatment of elderly patients with psoriasis.
[/qt]

Source: NO LINKS ALLOWED

Stelara (ustekinumab)

[qt]The use otf ustekinumab (UST) appears to be an appropriate systemic treatment because it is considered less likely to cause adverse events than other systemic treatments, as well as necessitating fewer hospital visits.

That's interesting. It is "likely" better, so it could be but also could not be. There is no indication to what other treatments they compared it. If the competitor is MTX, then I am quite sure it is better, but if it is DMF, then it is likely that it it's not likely.
There is no comparison material visible in this conclusion, so it is likely that we as receivers of this study are a bit critical on this conclusive message.
The range is also over only 1 year... Elderly people can be much older than 66.